Coronary artery diseasePregnancy Associated Plasma Protein A, a Novel, Quick, and Sensitive Marker in ST-Elevation Myocardial Infarction
Section snippets
Methods and Results
All patients referred to Rigshospitalet in Copenhagen, Denmark, from April 1, 2005, to December 31, 2005, for primary percutaneous intervention (pPCI) due to STEMI were included in the study. Guidelines for referral for pPCI due to STEMI were adapted from the Danish Trial in Acute Myocardial Infarction (DANAMI) 2 study: significant ST elevation (>1 mm in leads I, II, III, aVL, and aVF or >2 mm in leads V1 to V6) in ≥2 contiguous leads or newly developed left-bundle branch block and symptom
Discussion
This study shows that PAPP-A is elevated in >90% of patients presenting with STEMIs if measured <6 hours after the onset of symptoms or <2 hours after pPCI.
In the early stages of STEMI, PAPP-A is a more sensitive and earlier marker of myocardial infarction than CKMB and troponin T.
Circulating PAPP-A levels were originally measured by a competitive radioimmunoassay,20 but all recently published studies are based on ELISA techniques. Many assays for measuring PAPP-A are currently available,
References (20)
- et al.
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP
Atherosclerosis
(2003) - et al.
Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis
J Am Coll Cardiol
(2005) - et al.
Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease
Clin Biochem
(2002) - et al.
Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patients
Clinca Chimica Acta
(2004) - et al.
Circulating pregnancy-associated plasma protein A is not an early marker of acute myocardial infarction
Clin Biochem
(2005) - et al.
Optimisation of sandwich ELISA based on monoclonal antibodies for the specific measurement of pregnancy-associated plasma protein (PAPP-A) in acute coronary syndrome
Clin Biochem
(2007) - et al.
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes
N Engl J Med
(2001) - et al.
Pregnancy-associated plasma protein a as predictor of outcome in patients with suspected acute coronary syndromes
Circulation
(2004) - et al.
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris
Circulation
(2004) - et al.
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris
Eur Heart J
(2005)
Cited by (46)
The effect of heparin on pregnancy associated plasma protein-A concentration in healthy, non-pregnant individuals
2015, Clinical BiochemistryCitation Excerpt :The original hypothesis of PAPP-A in ACS originating from the vulnerable plaque has led to a vast production of papers concerning this issue. The hopes were to find a biomarker to detect the vulnerable plaques and thereby help improving diagnostic and therapeutic decision-making in patients with ACS [23,24]. However, the findings have been inconsistent and the hypothesis has since been questioned on several points.
PAPP-A in cardiac and non-cardiac conditions
2013, Clinica Chimica ActaPathophysiological Roles and Clinical Importance of Biomarkers in Acute Coronary Syndrome
2013, Advances in Clinical ChemistryUsefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with st-segment elevation myocardial infarction undergoing primary percutaneous intervention
2012, American Journal of CardiologyCitation Excerpt :A total of 354 consecutive patients with suspected STEMI and a clinical indication for acute coronary angiography aimed at primary PCI were included in the present study from April 1, 2005 to December 31, 2005 at a single high PCI-volume tertiary invasive center in Copenhagen.3
The Biomarkers for Acute Myocardial Infarction and Heart Failure
2020, BioMed Research International